Replies to post #177433 on NorthWest Biotherapeutics Inc (NWBO)

[hankmanhub]

I agree and already knew what you posted. There are of course differences between L and Direct as you point out - and it is certainly within the realm of possibility that the differences could actual make for a different result. However, in the bigger picture, they are basically still mostly very similar ideas about exposing the DC at a critical point in their development to the tumor antigens (whether in lysate or by injection in vivo) and the chances are very good that you will in fact get similar results as many people assume quite naturally.

[Doc logic]

exwannabe,

You do not understand the MO of Direct. Besides utilizing previously damaged cells from treatments received I believe Direct causes cancer targets to be exposed by tricking the cancer to let down its guard and keeping activated/stimulated checkpoint blockades on the sidelines until the active immune response begins to subside and immune memory takes over. This is achieved not only by the treatment itself but also by proper spacing of treatments. Direct also shuts down new growth of the tumor which causes it to die from being cut off from access to nutrients and energy ie necrosis. If you understood this you would understand the enormous potential behind Direct and not sitting on the sidelines wondering if this company has any chance to succeed. Best wishes.

[flipper44]

"DC have been found in many of the major organs in mammals (e.g. skin, heart, lungs, intestines and spleen); while the brain has long been considered devoid of DC in the absence of neuroinflammation. Consequently, microglia, the resident immune cell of the brain, have been charged with many functional attributes commonly ascribed to DC. Recent evidence has challenged the notion that DC are either absent or minimal players in brain immune surveillance. This review will discuss the recent literature examining DC involvement within both the young and aged steady-state brain. We will also examine DC contributions during various forms of neuroinflammation resulting from neurodegenerative autoimmune disease, injury, and CNS infections. This review also touches upon DC trafficking between the central nervous system and peripheral immune compartments during viral infections, the new molecular technologies that could be employed to enhance our current understanding of brain DC ontogeny, and some potential therapeutic uses of DC within the CNS." https://www.ncbi.nlm.nih.gov/pubmed/22825593

[jondoeuk]

Many? The only ''success'' was Provenge. The rest (200+) have all failed.